Literature Review of 14 Cases of Adverse Reactions to Bevacizuma
Objective:To analyze the characteristics of adverse drug reactions(ADR)caused by bevacizumab to provide reference for safe clinical use.Methods:Retrieve case reports of bevacizumab ADR from the databases of China National Knowledge Infrastructure,Wanfang,VIP,and PubMed up to March 2023,and conduct statistical analysis on patients'gender,age,tumor type,occurrence time of ADR,involvement of systems/organs,symptomatic treatment,and outcomes.Results:14 case reports of bevacizumab ADR were included,involving 14 cases.Among them,there were 5 males(35.71% )and 9 females(64.29% );the age range was 36 to 70 years old,with an average age of(55.79±10.10)years;There were 4 cases of non-small cell lung cancer(28.57% ),5 cases of colorectal cancer(35.71% ),1 case of skin squamous cell carcinoma,1 case of ovarian cancer,1 case of breast cancer,1 case of malignant melanoma,and 1 case of cervical squamous cell carcinoma(7.14% ).5 cases(35.71% )of patients developed ADR after their first medication;4 patients(28.57% )experienced ADR within 1 medication cycle;3 patients(21.43% )experienced ADR within 2 medication cycles;2 patients(14.29% )developed ADR after 3 medication cycles.ADR affects systemic diseases,gastrointestinal diseases,cardiovascular diseases,neurological diseases,skin and skin accessory diseases,metabolic and nutritional diseases,mental sickness and respiratory system diseases with 6 cases(42.86% )involving multiple systems/organs.13 patients(92.86% )showed significant improvement in ADR after discontinuing medication and receiving active symptomatic treatment,while 1 patient(7.14% )died.Conclusion:Clinical monitoring of bevacizumab ADR should be strengthened,and ADR should be detected in a timely manner and treated accordingly to improve the safety of clinical medication and patient prognosis.
bevacizumabtumoradverse drug reactionliterature reviewclinical monitoring
万方数据
维普
